Clinical Trials · NCT07057622

A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs

Name: A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

RecruitingPhase 3Octreotide

Phase: Phase 3
Recruitment status: Recruiting
Sponsor: HTA Co., Ltd.
Enrollment: 184
Start date: Dec 2023
Locations: 1 site, China
Primary endpoint: Compare the 18-month PFS rate of NET patients between 177Lu-DOTATATE Injection and long-acting octreotide

View Octreotide compound reference